Zhu L, Li M, Zha Q, et al. - Researchers sought to determine if fibroblast growth factor 21 (FGF21) could be a biomarker to predict osteoporosis in a haemodialysis cohort. A total of 339 haemodialysis patients from two large medical centres were analyzed, in terms of demographic information, biochemical data, and serum FGF21 and fibroblast growth factor 23 levels and CT attenuation values. A positive link of FGF21 with the incidence of osteoporosis was found in patients receiving haemodialysis. The combination of FGF21 and age was identified as a good predictive biomarker for osteoporosis in this study population, particularly in those with less residual kidney function.